MOTS-c is a short mitochondria-derived signal studied in cellular energy regulation and metabolic adaptation. Clinic and community discussions connect it with exercise and body-composition goals; the original experiments here measured effects in cells and mice.
Research focus: Metabolic signaling and exercise-related interest.
Choose a compound to open its research, documentation and calculator.
No FDA-approved drug product for this catalog material. Compounding eligibility and approval are separate questions.
Official source ↗PeptIQ’s reported value has not been matched here to a primary human PK study for the exact molecule and route. Treat it as a reference estimate, not an established dosing interval.
Half-life describes concentration falling by half. It does not set a dosing interval, a storage period or a drug-test detection window.
Kinetics source ↗PeptIQ lists bacteriostatic water for repeated-vial workflows. That preference is not a compatibility study for a particular formulation; the actual product or pharmacy instructions determine the liquid.
Bacteriostatic water contains a preservative; plain sterile water does not. Preservative presence does not by itself establish compatibility or a mixed medicine’s usable period.
Preparation source ↗The animal and cell findings do not establish a human weight-loss dose or injection schedule.
Check that a source concerns the same molecule, formulation, route and population. A study of cells, animals or a different product cannot confirm the contents of a vial.
Preclinical metabolic findings, with clinic and online protocols labeled separately.
Other names you may encounter: MOTSc.
Learn to read a study →Each entry keeps one schedule’s amount, frequency and cycle together. Community references, individual reports, clinical trials and prescription products describe different kinds of use. A missing duration or break stays marked as not reported.
Amounts describe mass in mg or mcg. Syringe units describe volume and depend on concentration. A cycle break is different from days off within a week.
Choose an option to explore its amounts, timing and cycle.
Four 5 mg administrations total 20 mg within the 20-day block.
This option totals 3.5–7 mg over a seven-day week.
| When | Amount & frequency |
|---|---|
| First 4–6 weeks | 5 mg three times weekly |
| Next 2–4 weeks | 10 mg once weekly |
This individual sequence began after 10–20 days of SS-31. It is separate from simultaneous use.
Community identifies source origin. It does not certify independent funding, medical credentials or the strength of a claim. Source types distinguish published reports, professional explanations and public discussions.
Explore reports, explanations and discussions from medical practices, researchers, suppliers and community members. The badges identify the source’s origin and evidence type.
How to read these source labels →Timing wording conflicts within the article.
Source relationship: Commercial treatment provider.
The clinic describes four administrations followed by a longer break.
Clinic description · not a controlled trial
No direct human comparison establishes a preferred schedule.
Source relationship: Promotes a peptide-tracking app.
The article compares smaller daily amounts with larger intermittent amounts. Our guide separates the weekly arithmetic from the proposed AMPK rationale.
Online explanation · commercial app
A peptide name and vial mass cannot determine a compatible diluent, powder displacement, storage temperature or discard date. Follow the exact product’s instructions and your pharmacist’s directions.
The injection guide concerns clinician-prescribed subcutaneous medicines; it does not establish that a research-labeled material can be injected.
Start with the formulation: dry powder, prepared solution, pen, tablet and topical product can have different instructions.
On a U-100 syringe, 25 units = 0.25 mL. That volume contains 5 mg only at 20 mg/mL. At 10 mg/mL, the same 25 units contains 2.5 mg. These are concentration examples, not mixing instructions.
Check the arithmetic with your documented inputs ↓Storage claims conflict. MOTSc.com says seven days after mixing, while Path To Peptides says 30 days. A website’s generic number does not establish stability or sterility for another formulation. Use documented formulation-specific handling and discard information; refrigeration alone cannot verify a usable period. Seven-day claim ↗ · 30-day claim ↗
General health habits and consistent observations help you assess changes. They are not evidence that a peptide’s effects will be amplified.
Choose activity that fits your health and ability. Aerobic movement and muscle-strengthening work are part of general adult activity guidance.
CDC · adult activity ↗Use a regular sleep/wake schedule and note changes in sleep quality alongside symptoms or training.
CDC · sleep habits ↗What to record: Track food intake, appetite, activity and tolerability together. Appetite control should still leave room for adequate meals; review persistent eating difficulties with the treating clinician.
Check dates are editorial references, not a medical review certificate. Labels and evidence can change; consult the linked current document.
The clinic’s example places 5 mg administrations on days 1, 6, 11 and 16: 20 mg across the block. The final administration is on day 16 of the described 20-day window, not day 20.
These comparisons show arithmetic, not bioequivalence. There is no established conversion from a weekly total to an equally safe or effective daily schedule. Clinic explainers and commercial online guides are not head-to-head clinical trials.
Path To Peptides gives these three examples. Its 3.3 mg entry totals 9.9 mg, rounded to about 10 mg weekly.
| Amount each time | Reported frequency | Weekly total |
|---|---|---|
| 5 mg | Once weekly | 5 mg |
| 2.5 mg | Twice weekly | 5 mg |
| 3.3 mg | Three times weekly | 9.9 mg |
Cycle length belongs to its source. Lamkin’s 8–12-week example accompanies 5 mg per injection three to five times weekly—15–25 mg weekly. Its longer cycle cannot simply be attached to the lower weekly amounts above. Check the clinic’s full schedule ↗
PeptIQ argues for more consistent AMPK signaling with smaller daily amounts. That is a proposed rationale; the article does not provide a human comparison proving steady signaling, better outcomes or lower risk. Read the publisher’s rationale ↗
Lamkin favors mornings or 30–60 minutes before exercise. Perfect B’s detailed instructions say morning before food, but its opening summary says bedtime. These descriptions do not establish a best time or a requirement to fast. Lamkin’s timing description ↗ · Perfect B’s differing wording ↗
Clinic pages discuss injection-site reactions and possible glucose-lowering effects, especially alongside metabolic medicines. They also advise caution around pregnancy, breastfeeding and active cancer. These are practitioner precautions, not a complete, regulator-approved contraindication or interaction list. Reliable human adverse-event rates are not established by the linked explainers.
FDA identifies limited human exposure information and concerns about immunogenicity, peptide impurities and product characterization. The schedules above do not resolve those gaps; neither “research use only” nor a clinic’s description constitutes drug approval. Read FDA’s MOTs-C entry ↗
Opening values and worked examples illustrate arithmetic; they are not preparation instructions or recommended amounts. Selecting a compound labels the calculation and does not supply a dose or powder-volume correction.
Enter the documented vial mass, preparation information and target amount to see how mass and volume connect.
20 mg in an assumed final 1 mL gives 20 mg/mL. An entered 1 mg corresponds to 0.05 mL, or 5 U-100 units, with 20 theoretical portions before losses.
Estimate · assumes 1 mL added = total volume
1,000 mcg
Theoretical · before losses
0.2 mL
After 5 full doses
Illustration only · calculated value, without rounding
Saved calculations stay on this device.
Concentration = mass ÷ final volume
5 mg ÷ 1 mL = 5 mg/mLVolume = target mass ÷ concentration
1 mg ÷ 5 mg/mL = 0.2 mLU-100 markings = volume × 100
0.2 mL × 100 = 20 unitsComplete portions = floor(vial mass ÷ amount per portion).
Displayed numbers are rounded for readability; the calculation uses unrounded values.
Already have the concentration? Find the matching mL and U-100 syringe reading.
Need the concentration first? Use the Reconstitution tab.
5units
0.05 mL · 0.25 mg
0.25 mg ÷ 5 mg/mL = 0.05 mLU-100 units = mL × 100Example inputs are editable. The reading is calculated without rounding to a physical graduation.
Convert mass or liquid volume. U-100 markings always refer to a 100-units-per-mL scale.
1,000mcg
For mass → syringe volume, switch to Dosage and enter a concentration.